Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results

Iovance Biotherapeutics (NASDAQ:IOVA) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02, Briefing.com reports. The firm had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The company’s revenue for the quarter was up 65.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.33) earnings per share.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Record second-quarter performance: Revenue reached $99.3 million, up 66% year over year and 39% sequentially, led by approximately $91 million in Amtagvi sales that exceeded guidance. Gross margin rose to a record 56% as manufacturing volume and in-house efficiencies improved.
• Commercial adoption continues to broaden. Iovance reported more than 95 Authorized Treatment Centers, including a growing community-based presence, and expects at least 110 centers by year-end; management said demand remained strong entering the third quarter.
• Pipeline milestones advanced: Enrollment is nearly complete in the pivotal lung cancer trial, with an update expected in the fourth quarter and a potential supplemental filing targeted for 2027. Lifileucel also received FDA Fast Track designation in two soft-tissue sarcoma indications, while early endometrial and serous cancer data supported a protocol amendment aimed at an expedited approval pathway.
• Financial flexibility improved. Cash, cash equivalents, and short-term investments totaled approximately $304 million at June 30, which management expects to fund operations into the second half of 2028; research and development expenses declined for the fourth consecutive quarter.
• The company is reviewing its 2026 total revenue guidance of $350 million to $370 million and expects to issue an update during the third quarter. Management characterized the revision as driven by improved visibility into demand, but the updated outlook and timing remain unspecified.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA traded up $0.13 during midday trading on Friday, hitting $6.34. 30,912,913 shares of the company’s stock were exchanged, compared to its average volume of 19,318,560. The stock has a 50 day moving average price of $4.40 and a 200-day moving average price of $3.80. The company has a market cap of $2.83 billion, a PE ratio of -8.68 and a beta of 0.71. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $6.92.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IOVA. Robert W. Baird set a $6.00 price objective on Iovance Biotherapeutics in a report on Friday. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday. Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Barclays raised their price target on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. Granite Investment Partners LLC purchased a new position in shares of Iovance Biotherapeutics during the fourth quarter valued at approximately $29,000. Motley Fool Asset Management LLC purchased a new stake in Iovance Biotherapeutics in the 4th quarter valued at $29,000. Dynamic Technology Lab Private Ltd bought a new position in Iovance Biotherapeutics during the 4th quarter valued at $46,000. HighTower Advisors LLC lifted its stake in Iovance Biotherapeutics by 67.9% during the 4th quarter. HighTower Advisors LLC now owns 19,089 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 7,718 shares in the last quarter. Finally, Diversify Wealth Management LLC purchased a new position in Iovance Biotherapeutics during the 2nd quarter worth $34,000. 77.03% of the stock is owned by institutional investors.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
• Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
• Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
• Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
• Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
• Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.